# A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

> **NCT00449605** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 508 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Rimonabant
- **DRUG:** Glimepiride
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00449605
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2008-11
- **Final completion:** 2009-03
- **Target enrollment:** 508 (ACTUAL)
- **Why stopped:** Company decision taken in light of demands by certain national health authorities
- **Last updated:** 2016-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00449605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00449605, "A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00449605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*